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Introduction: Targeting signal transducer and activator of transcrip-
tion 3 (STAT3), a transcription factor that modulates  survival-directed 
transcription, is often persistently activated in epidermal growth factor 
receptor (EGFR) wild-type non–small-cell lung cancer (NSCLC). The 
aim of this study was to determine whether sorafenib and its deriva-
tive can inhibit EGFR wild-type NSCLC via STAT3 inactivation.
Methods: EGFR wild-type NSCLC cell lines (A549 H292 H322 
H358 and H460) were treated with sorafenib or SC-1, a sorafenib 
derivative that closely resembled sorafenib structurally but was 
devoid of kinase inhibitory activity. Apoptosis and signal transduc-
tion were analyzed. In vivo efficacy was determined in nude mice 
with H460 and A549 xenograft.
Results: SC-1 had better effects than sorafenib on growth inhibi-
tion and apoptosis in all tested EGFR wild-type NSCLC lines. SC-1 
reduced STAT3 phosphorylation at tyrosine 705 in all tested EGFR 
wild-type NSCLC cells. The expression of STAT3-driven genes, 
including cylcin D1 and survivin, was also repressed by SC-1. 
Ectopic expression of STAT3 in H460 cells abolished apoptosis in 
SC-1–treated cells. Sorafenib and SC-1 enhanced Src homology-2 
containing protein tyrosine phosphatase-1 (SHP-1) activity, whereas 
knockdown of SHP-1, but not SHP-2 or protein-tyrosine phosphatase 
1B (PTP-1B), by small interference RNA reduced SC-1–induced 
apoptosis. SC-1 significantly reduced H460 and A549 tumor growth 
in vivo through  SHP-1/STAT3 pathway.
Conclusions: SC-1 provides proof that targeting STAT3 signal-
ing pathway may be a novel approach for the treatment of EGFR 
 wild-type NSCLC.
Key Words: Sorafenib, Cyclin D1, Survivin, Non–small-cell lung 
cancer, STAT3.
(J Thorac Oncol. 2014;9: 488–496)
Lung cancer is the leading cause of cancer-related deaths worldwide. More effective therapies are needed because of 
the poor survival rates. Lung cancer is broadly classiﬁed into 
two major categories: small-cell lung cancer and non–small-
cell lung cancer (NSCLC). Clinical reports show that 80% 
of lung cancers are diagnosed with NSCLC.1  Platinum-based 
chemotherapy has become the standard treatment for NSCLC 
based on the results from a number of clinical trials.2–4 Presently, 
target therapies with little or minor side effects may compen-
sate for the incompleteness of conventional chemotherapies. 
Epidermal growth factor receptor (EGFR) mutations are identi-
fied in 10% to 15% of white patients, and even higher in Asian 
patients.5 Patients with certain EGFR mutations have a higher 
response rate to an EGFR-targeted drug, geﬁtinib (Iressa; 
AstraZeneca, Wilmington, DE), than those with wild-type 
EGFR.6–9 However, carrying EGFR mutations does not assure 
NSCLC patients of sensitivity to EGFR inhibitors.10–12 Thus, it 
is important to develop more effective therapeutic strategies for 
treating NSCLCs that are resistant to current therapies.
Signal transducer and activator of transcription 3 
(STAT3) is a transcription factor that regulates cell growth and 
survival by modulating the expression of target genes.13 It acts 
as an oncogene that is constitutively active in many cancers, 
including liver, lung, head and neck, prostate, and breast can-
cer, as well as myeloma and leukemia.14–18 A key factor that 
regulates STAT3 activity is Src homology-2 containing protein 
tyrosine phosphatase-1 (SHP-1). From a mechanistic perspec-
tive, SHP-1 exhibits protein phosphatase activity that reduces 
the level of phospho-STAT3 (p-STAT3) and subsequently 
blocks the dimerization of p-STAT3. Thus, the expression of 
target genes, such as cyclin D1 and survivin, are signiﬁcantly 
reduced. Moreover, extensive studies of SHP-1 protein and 
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SHP-1 mRNA show that the expression level of SHP-1 is low 
in most cancer cells. The increased SHP-1 gene expression in 
cancer cells results in the suppression of cell growth, suggest-
ing that the SHP-1 gene acts as a tumor suppressor.19
Dysregulation of STAT3 activity is associated with the 
pathogenesis of numerous types of cancers including breast, 
colon, cervical, and prostate cancers.18 Several lines of evidence 
also indicate the correlation between STAT3 activity and patho-
genesis of lung cancer.20,21 There is a strong correlation between 
STAT3 activation and tumorigenesis, and suppression of STAT3 
by genetic or pharmaceutical modalities has antitumor effects 
in vivo and in vitro.22 Sorafenib (BAY43-9006; Nexavar; Bayer, 
West Haven, CT) is used clinically for renal carcinoma and 
hepatocellular carcinoma. It targets the c-Raf and b-Raf kinases 
and prolongs survival. Studies show that sorafenib can reduce 
the phosphorylation level of STAT3 in medulloblastoma and 
esophageal carcinoma.23,24 Further studies show that sorafenib 
reduces p-STAT3 by activating SHP-1 phosphatase activity 
in hepatocellular carcinoma cells.25 Because of the ability of 
sorafenib to reduce the p-STAT3 level, a novel sorafenib ana-
logue, SC-1, was synthesized.25–27 SC-1 retains the ability to 
reduce cell survival but does not affect Raf kinase activity. This 
study aims to provide evidence that SC-1 mediates apoptosis 
via decrease of STAT3 phosphorylation rather than Raf activity.
MATERIALS AND METHODS
Cell Lines and Culture
Five EGFR wild-type NSCLC cell lines were used in 
this study. The A549 (bronchioloalveolar carcinoma [BAC], 
mutant v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
[KRAS], cyclin-dependent kinase inhibitor 2A [CDKN2A], 
and serine/threonine kinase 11 [STK11]), H322 (BAC, 
mutant TP53 and CDKN2A), H292 (squamous cell carci-
noma,  wild-type KRAS), and H358 (BAC, mutant KRAS) 
cell lines were obtained from the American Type Culture 
Collection (Manassas, VA) whereas the H460 (large-cell 
lung cancer, mutant KRAS, PIK3CA, STK11, and CDKN2A) 
cell line was from the Buoresource Collection and Research 
Center (Hsinchu, Taiwan). The NSCLC cell lines were kept in 
RPMI1640 supplemented with 10% fetal bovine serum, 100 
units/ml penicillin G, and 100 μg/ml streptomycin sulfate in 
a 37°C humidified incubator with 5% carbon dioxide in air.
Reagents and Antibodies
Sorafenib (Nexavar) was provided by Bayer 
Pharmaceuticals (West Haven, CT). For in vitro studies, 
sorafenib and SC-125–27 at various concentrations were dis-
solved in dimethyl sulfoxide (DMSO) and then added to cells 
in serum-free RPMI1640. Sodium vanadate, SHP-1, SHP-2, 
and protein-tyrosine phosphatase 1B (PTP1B) inhibitors were 
purchased from Merck (Calbiochem). Antibodies for immu-
noblotting, such as anti–SHP-1, were purchased from Santa 
Cruz Biotechnology (San Diego, CA) and anti-Flag (M2) were 
from Sigma-Aldrich (St. Louis, MO). Other antibodies, such as 
anti–cyclin D1, phospho-STAT3 (Tyr705), STAT3 poly(ADP-
ribose) polymerase (PARP)  SHP-2, PTP-1B, survivin, and 
caspase-9, were from Cell Signaling (Danvers, MA).
Cell Viability Assay and Apoptosis Analysis
Five EGFR wild-type NSCLC cells were seeded in 96-well 
plate (2.5 × 103 cells/well). To determine cell viability and pro-
liferation, 10% WST-1 (water-soluble tetrazolium monosodium 
salt; Cell Proliferation Reagent WST-1; Roche Applied Science, 
Indianapolis, IN) agent was added to the cell suspension in each 
well for 0.5 to 3 hours of incubation. This colorimetric assay was 
based on the cleavage of the membrane-permeable tetrazolium 
salt WST-1 to produce a formazan-class dye. The reaction was 
catalyzed by a mitochondrial reductase in active cells and the 
amount of formazan dye was quantified by measuring the absor-
bance at 450 nm by using the Bio-Rad ELISA Reader (Bio-Rad, 
Hercules, CA) to calculate optical density values (A450nm–
A655nm). Statistical analysis was done using Student’s t test, 
with p value less than 0.05 considered statistically significant. 
Apoptotic cells were measured by flow cytometry (sub-G1) and 
cell death detection was by Western blot.
Immunocytochemistry for STAT3 Localization
Sorafenib and SC-1–treated cells were plated on a glass 
slide and fixed in 4% formaldehyde and ice acetone. After 
brief washing in phosphate-buffered saline, the slides were 
blocked with 5% normal goat serum for 1 hour and incubated 
with rabbit polyclonal antihuman STAT3 antibody (dilution, 
1:100). After overnight incubation, the slides were washed 
and then incubated with goat antirabbit IgG-FITC (1:200) 
for 1 hour and counterstained for nuclei with DAPI for 10 
minutes. The stained slides were mounted and analyzed under 
an epifluorescence microscope (Leica). Pictures were cap-
tured with the use of a Leica Photometrics CoolSNAP EZ 
 (high-performance charge-coupled device [CCD] and elec-
tron-multiplying CCD [EMCCD] cameras) and MetaMorph 
version software (Molecular Devices, Wetzlar, Germany).
Ectopic Expression of STAT3
The STAT3 cDNA plasmid was described previously.25 
In brief, after transfection, the cells were incubated in the pres-
ence of G418 (0.78 mg/ml). After 8 weeks of selection, sur-
viving colonies, that is, those arising from stably transfected 
cells, were selected and individually amplified. H460 cells with 
stable expression of STAT3 were then treated with sorafenib or 
SC-1, harvested, and processed for Western blot analysis.
SHP-1 and Raf-1 Activity Assay
After sorafenib or SC-1 treatment, H460 protein extract 
were incubated with anti–SHP-1 antibody in immunoprecipi-
tation buffer overnight. Protein A/G sepharose fast flow (GE 
Healthcare, Madison, WI) was added to each sample, followed 
by incubation for 3 hours at 4°C with rotation. SHP-1 activity 
assay kit (DuoSet IC activity assay, DYC2808; R&D systems, 
Minneapolis, MN) was used for SHP-1 tyrosine phospha-
tase activity. The Raf-1 kinase assay kit (Upstate-Millipore, 
Billerica, MA) was used to examine the Raf-1 kinase activity.
Gene Knockdown Using siRNA
Smart-pool siRNA, including control (D-001810-10), 
SHP-1, SHP-2, and PTP-1B were all purchased from 
Dharmacon Inc. (Chicago, IL). The procedure has been 
described previously.25–27
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Xenograft Tumor Growth
Male NCr nude mice (5–7 weeks of age) were used. All 
experimental procedures using these mice were performed 
according to protocols approved by the Institutional Laboratory 
Animal Care and Use Committee of Cardinal Tien Hospital. Each 
mouse was inoculated subcutaneously in the dorsal flank with 
1 × 107 of H460 cells and 5 × 106 A549 cells suspended in 0.1 ml of 
serum-free medium containing 50% Matrigel (BD Biosciences, 
Bedford, MA). When tumors reached 100 to 200 mm3, the mice 
were given sorafenib tosylate (10 mg/kg) by mouth once daily, or 
SC-1(10 mg/kg) by mouth once daily. The controls received vehi-
cle. The tumors were measured twice weekly by using calipers and 
their  volumes calculated using the following standard formula:
Width × length × height × 0.52326
Immunohistochemistry
Personal identities were encrypted and all data were 
analyzed anonymously. Because information that could be 
used to identify beneficiaries was scrambled, the Institutional 
Review Board of Cardinal Tien Hospital approved this study 
protocol and waived the requirement of informed consent. 
Immunohistochemical (IHC) stains were performed, using the 
Ventana BenchMark XT automated stainer (Ventana, Tucson, 
AZ). In brief, 4-μm thick sections would be cut consecutively 
from formalin-fixed, paraffin-embedded human tissue. Sections 
would be mounted and allowed to dry overnight at 37°C. After 
deparaffinization and rehydration, slides would be incubated with 
3% hydrogen peroxide solution for 5 minutes. After a washing 
procedure with the supplied buffer, tissue sections were repaired 
for 40 minutes with ethylenediamine tetra-acetic acid. The slides 
will be again incubated with the primary antibody for 60 min-
utes at 37°C and then overnight at 4°C. The primary antibody, 
p-STAT3 (1:50; Cell Signaling) and stat3 (1:200; Cell Signaling) 
were performed. After three rinses in buffer, the slides were incu-
bated with the secondary antibodies (unbiotinylated antibody; 
EnVisionTM System; HRP, anti-mouse/rabbit, DakoCytomation; 
Dako, Glostrup, Denmark). Tissue staining will be visual-
ized with a 3,3′-diaminobenzidine (DAB) substrate chromogen 
solution (DakoCytomation). Slides will be counterstained with 
hematoxylin, dehydrated, and mounted. Each run included, for 
each patient, phosphate-buffered solution used as the primary 
antibody for the negative controls, whereas samples known to 
express these markers strongly served as the positive controls.
Statistical Analysis
Statistical analysis was performed using a two-tailed 
Student’s t test. The results were expressed as mean ± standard 
error of the mean. Differences were considered significant at p 
value less than 0.05 and highly significant at p value less than 0.01.
RESULTS
SC-1 Caused Cell Death Effect in EGFR 
Wild-Type NSCLC Cell Lines
In terms of the relationship between SC-1 and sorafenib 
Raf-1 activity, there was a significant reduction in Raf-1 kinase 
activity in the presence of sorafenib, but no reduction in Raf-1 
kinase activity in the presence of SC-1, suggesting that SC-1 was 
not a kinase inhibitor like sorafenib (Fig. 1A). After examining 
the antiproliferation effects of sorafenib and SC-1, both SC-1 
and sorafenib decreased the viability of various EGFR wild-type 
NSCLC cells, including A549, H292, H322, H358, and H460 in 
a dose-dependent manner for 24 hours (Fig. 1B).
To determine whether SC-1 induced cell death, apopto-
sis was measured by propidium iodide (PI) staining of DNA. 
SC-1 induced apoptosis from 20% to 50% in SC-1–treated 
cells within 24 hours at 10 μM, especially at H460 cells (Fig. 
1C).  Apoptosis-related gene activation of caspase-9 and PARP 
cleavage was also measured (Fig. 1D). SC-1 cleaved procas-
pase-9, which led to the appearance of caspase-9, and cleaved 
PARP. Taken together, all of these suggested that SC-1 could 
induce apoptosis in human NSCLC cells, indicating that SC-1 
was highly cytotoxic to tumor cells.
STAT3 Was An Important Candidate 
of Sorafenib and SC-1 in EGFR 
Wild-Type NSCLC Cell Line
To verify whether the phosphorylation of STAT3 was 
regulated by SC-1, the STAT3-related signaling pathway was 
assayed in SC-1–treated NSCLC cells (i.e., A549, H322, 
H292, H358, and H460). STAT3 showed reduced phosphory-
lation by SC-1, which resulted in the induction of cell death, 
as well as apoptosis-related molecules like cyclin D1 and sur-
vivin. The phosphorylation of STAT3 at tyrosine 705 was criti-
cal for STAT3 transactivation. SC-1 and sorafenib decreased 
phosphorylation of STAT3 at the Y705 residue and suppressed 
cyclin D1 in NSCLC cells (Fig. 2A). Moreover, SC-1 and 
sorafenib reduced STAT3 phosphorylation in a dose- and time-
dependent manner (Fig. 2B, top and lower).
The activation status of p-STAT3 was measured by 
STAT3 ELISA, human Duoset ELISA development kit (R&D 
Systems, Minneapolis, MN). The results showed that sorafenib 
and SC-1 significantly decreased the activity of p-STAT3. SC-1 
and sorafenib affected STAT3 phosphorylation activity (Fig. 
2C). Using STAT3-overexpressing stable clones of NSCLC 
cells, it was observed that both sorafenib and SC-1 suppressed 
the expression of p-STAT3 in STAT3-overexpressed H460 cells, 
suggesting that STAT3 was a major mediator of sorafenib- and 
SC-1–induced apoptosis (Fig. 2D). STAT3 was dominantly 
localized to the nuclear compartment of untreated cells by 
immunofluorescence. On the contrary, sorafenib and SC-1 treat-
ment lead to STAT3 predominantly cytoplasmic localization so 
the drugs prevent STAT3 nuclear accumulation (Fig. 2E).
SC-1 Inhibition of STAT3 Activation 
Involved a Protein Tyrosine Phosphatase
Several protein phosphatases involved in regulating 
p-STAT3 were examined. Sodium vanadate decreased apopto-
sis and restored STAT3 phosphorylation (Fig. 3A, left lane, 5 
and 6). Furthermore, SHP-1 phosphatase-specific inhibitor, but 
not SHP-2 inhibitor (Fig. 3A, right), reversed the SC-1– and 
sorafenib-induced cell death and inhibition of p-STAT3 (Fig. 
3A, middle). To further verify the role of SHP-1 in SC-1– and 
sorafenib-induced inhibition of p-STAT3, siRNA strategy spe-
cific to SHP-1 was applied to examine the influence of sorafenib 
and SC-1. Silencing of SHP-1 reversed the sorafenib- or 
SC-1–induced apoptosis and inhibition of p-STAT3 (Fig. 3B).
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In addition, both sorafenib and SC-1 increased SHP-1 
activity compared with controls (p<0.05). Sorafenib- or 
SC-1–treated H460 cells were immunoprecipitated by 
 SHP-1–specific antibody. The SHP-1–containing complex 
then underwent fluorescence-based phospho-group assay. 
Neither sorafenib nor SC-1 affected the interaction of 
STAT3 and SHP-1, as evidenced by SHP-1 immunopre-
cipitation (Fig. 3C), suggesting that sorafenib induced cell 
FIGURE 1.  SC-1 had anticancer effects similar to sorafenib in NSCLC cells. A, Left panel, chemical structure of sorafenib or 
SC-1. Right panel, effect of sorafenib or SC-1 on Raf-1 activity. H460 cells were exposed to sorafenib or SC-1 at 10 μM for 24 
hours. Points, mean; bars, SD (n=3). B, Dose-escalation effects of sorafenib or SC-1 on cell viability in five NSCLC cell lines. Cells 
were exposed to sorafenib or SC-1 at the indicated doses for 24 hours. Cell viability was measured by water-soluble tetrazolium 
monosodium salt–1 assay. Points, mean; bars, SD (n=3). *p < 0.05; **p < 0.01. C, Dose-escalation effects of sorafenib or SC-1 on 
apoptosis in five NSCLC cell lines, as analyzed by flow cytometry. Points, man; bars, SD (n=3). D, Apoptosis effects of sorafenib 
or SC-1 SC-1 in five NSCLS cell lines, as analyzed by Western blot. NSCLC, non–small-cell lung cancer; DMSO, dimethyl sulfoxide;  
PARP, poly(ADP-ribose) polymerase. 
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FIGURE 2.  SC-1 reduced STAT3 phosphorylation in NSCLC cells. A, Effects of sorafenib or SC-1 on STAT3-related proteins. Cells 
were exposed to sorafenib or SC-1 at the indicated doses for 24 hours. B, Dose-escalation (top) and time-dependent (lower) 
effects of sorafenib or SC-1 on phospho-STAT3 in H460 cells. Cells were treated with sorafenib or SC-1 at 10 μM for 24 hours. C, 
Effects of sorafenib and SC-1 on STAT3 activity, phospho-STAT3 enzyme-linked immunosorbent assay (ELISA). Points, man; bars, 
SD (n=3) **p < 0.01. D, Protective effects of STAT3 on apoptosis induced by sorafenib or SC-1 in H460 cells. Cells were exposed 
to sorfenib or SC-1 at 10 μM for 24 hours. Apoptotic cells were analyzed by flow cytometry. Columns, mean; bars, SD (n=3)  
**p < 0.01. E, Untreated and two drugs-treated cells were analyzed by fluorescence microscopy. DAPI staining and overlay dem-
onstrated nuclear accumulation of STAT3 in untreated, but not in sorafenib- or SC-1–treated cells. STAT3, signal transducer and 
activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. 
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death through  SHP-1–dependent STAT3 inactivation. The 
effects of sorafenib on apoptosis and p-STAT3 were not 
reversed by silencing SHP-2 or PTP-1B (data not shown) 
(Fig. 3D), suggesting that neither SHP-2 nor PTP-1B 
played a role in mediating the effects of sorafenib or SC-1 
on p-STAT3.
Therapeutic Evaluation of Effect of SC-1 and 
Sorafenib on H460 or A549-Bearing Mice
To verify the therapeutic effect of SC-1, SC-1 was 
applied to the NSCLC xenograft to evaluate its significance 
in vivo. SC-1 treatment significantly inhibited H460 or A549 
xenograft tumor growth and SC-1 treated animals had tumor 
FIGURE 3.  Inhibition of SHP-1 reversed the effects of sorafenib and SC-1 on phospho-STAT3 and apoptosis. A, Left panel, vanadate, 
a nonspecific phosphatase inhibitor; middle panel, specific SHP-1 inhibitor; right panel, specific SHP-2 inhibitor; Columns, mean; bars, 
SD (n=3) *p < 0.05. B, Silencing of SHP-1 by siRNA reduced the effects of sorafenib or SC-1 on p-STAT3 in H460 cells. Columns, mean; 
bars, SD (n=3) *p < 0.05, **p < 0.01. C, Effects of sorafenib or SC-1 on protein interactions between SHP-1 and STAT3. D, Knockdown 
of SHP-2 and PTP-1B did not affect the effects of sorafenib or SC-1 on p-STAT3 and apoptosis. H460 cells were transfected with control 
siRNA or SHP-2 siRNA or PTP-1B siRNA for 48 hours then treated with sorafenib or SC-1 at 10 μM for 24 hours. SHP-1, Src homol-
ogy-2 containing protein tyrosine; STAT3, signal transducer and activator of transcription 3; PTP-1B, protein-tyrosine phosphatase 1B; 
DMSO, dimethyl sulfoxide; IP, immunoprecipitation. 
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sizes that were less than half of those of control mice (Fig. 4A 
and D). There were no apparent differences in body weight or 
toxicity in any mice (data not shown).
To further correlate the molecular mechanism of 
sorafenib with its anticancer effect in vivo, tumor extract 
from vehicle, SC-1–treated , and sorafenib-treated mice 
were immunoblotted for p-STAT3. p-STAT3 was decreased in 
SC-1–treated tumor (Fig. 4B and E). SHP-1 activity in SC-1–
treated and sorafenib-treated H460 or A549 xenografts were 
also examined. SC-1–treated tumor showed significant induc-
tion of SHP-1 activity in vivo (Fig. 4C and F). Taken together, 
these results confirmed that SC-1 could increase SHP-1 activ-
ity to repress p-STAT3 involved in tumor inhibition in the 
EGFR wild-type NSCLC xenograft model.
Expression of STAT3 and p-STAT3 by 
Immunohistochemistry in EGFR  Wild-
Type NSCLC Clinical Tissue Specimen
Immunohistochemistry was performed in EGFR 
 wild-type NSCLC specimen in which STAT3 and p-STAT3 
were overexpressed in tumor samples. The STAT3 and p-STAT3 
proteins were expressed in both cytoplasmic and nuclear com-
ponents of tumor cells with stronger signal (Fig. 5). However, 
the adjacent normal bronchial epithelia exhibited less STAT3 
and p-STAT3 staining.
DISCUSSION
This study demonstrates that SC-1, a sorafenib deriva-
tive that lacks hydrogen donor ability because of its pyridine 
ring and amide functional group being replaced by phenyl cya-
nide, has antitumor effects that equal those shown by sorafenib 
on EGFR wild-type NSCLC cells. Despite showing no Raf-1 
kinase inhibition activity in EGFR wild-type NSCLC cells, 
SC-1 still induces significant apoptosis and triggers p-STAT3 
inhibition in the same manner as sorafenib in EGFR wild-type 
NSCLC cells both in vitro and in vivo. On the basis of the 
results, SC-1, a novel compound that affects STAT3 in the 
same manner as sorafenib, has an anticancer effect on EGFR 
wild-type NSCLC cells. This anticancer effect is not corre-
lated with repression of Raf-1 kinase.
FIGURE 4.  In vivo effects of sorafenib 
and SC-1 on H460 and A549 xeno-
graft nude mice. A and D, Sorafenib 
and SC-1 show antitumor effects on 
H460 and A549 tumors. Points, mean 
(n=8); bars, standard error. B and E, 
Western blot analysis of p-STAT3 and 
STAT3 in H460 and A549 tumors. C 
and F, the activities of SHP-1 in H460 
and A549 tumors. Points, mean 
(n=8); bars, standard error. *p < 0.05; 
**p < 0.01. STAT3, signal transducer 
and activator of transcription 3; SHP-1, 
Src  homology-2 containing protein 
tyrosine.
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STAT3 activation is present in a substantial number of 
NSCLC cell lines and NSCLC tumor specimens, especially 
EGFR mutation NSCLC. Gao et al.28 pointed that p-STAT3 is 
found in primary adenocarcinomas and cell lines harboring 
somatic-activating mutations in the tyrosine kinase domain of 
EGFR. Jiang et al.29 detected p-STAT3 expression in lung can-
cer by immunohistochemistry in tissue from 127 lung carcino-
mas (100 adenocarcinomas and 27 squamous cell carcinomas). 
Among the 127 cases of NSCLC, p-STAT3 immunoreactivity 
is significantly correlated with sex (p=0.004), smoking history 
(p=0.006), EGFR mutation status (p=0.003), clinical stage 
(p=0.034), and lymph node metastasis (p=0.009). However, 
the role of STAT3 in EGFR wild-type NSCLC is nearly not 
mentioned. Data in the present study prove that STAT3 is also 
crucial in EGFR wild-type NSCLC and thus is a promising 
potential target for anticancer therapy.
This study demonstrates that the novel compound SC-1, 
as well as sorafenib, induces EGFR wild-type NSCLC cell 
death and represses p-STAT3 in NSCLC xenograft models 
through SHP-1–dependent STAT3 inactivation. Thus, STAT3 
seems to be a promising biological target for new therapeutic 
strategies for the treatment of EGFR wild-type NSCLC.
Clinically, the phase II trials of sorafenib in previ-
ously treated advanced NSCLC have failed.30,31 However, 
sorafenib has better effects in EGFR wild type and EGFR 
fluorescence in situ hybridization–negative patients with 
better  progression-free survival and overall survival.31 The 
present study shows that sorafenib has an anticancer effect 
on EGFR wild-type NSCLC cells through SHP-1–dependent 
STAT3 inactivation instead of Raf-1 kinase. Sorafenib should 
also have an effect on wild-type NSCLC if the patient group 
is carefully selected. Moreover, STAT3 pathway screening 
maybe an important condition for whether sorafenib has anti-
cancer effect on EGFR wild-type NSCLC patients. Aside 
from EGFR mutation, there are many gene abnormalities in 
NSCLC, such as echinoderm microtubule-associated protein-
like 4 and anaplastic lymphoma kinase (EML4-ALK) fusions, 
human epidermal growth factor receptor 2 (HER2), PIK3CA, 
protein kinase B or AKT (PKB/AKT), v-Raf murine sarcoma 
viral oncogene homolog B1 (BRAF), mitogen-activated pro-
tein kinase kinase 1 (MAP2K1), mesenchymal-epithelial 
transition (MET), and KRAS mutations.32,33 STAT3 pathway 
screening will be a promising method to screen candidates for 
sorafenib or SC-1.
In conclusion, STAT3, rather than Raf-1, is critical in the 
anticancer effect of sorafenib and its novel analogue SC-1 on 
NSCLC. Blocking STAT3 signaling by SC-1 may be a novel 
therapeutic approach for lung cancer.
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